Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Highlights from IMS 2022

Philip Murphy • 1 Sep 2022
Multiple Myeloma CAR-T

Philip Murphy, MD, Beaumont Hospital, Dublin, Ireland, gives his highlights from the International Myeloma Society (IMS) Meeting that was held in Los Angeles, CA, in August 2022. These include updates in CAR-T therapy for multiple myeloma and further insights into COVID-19 vaccination in patients with multiple myeloma. Prof. Murphy also highlights what he’s looking forward to hearing more about at ASH 2022, including the use of cellular therapies in multiple myeloma. This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Philip Murphy

1:28
Ongoing trials in multiple myeloma in Ireland
Philip Murphy • 1 Sep 2022
1:24
Treating patients with relapsed/refractory myeloma in Ireland
Philip Murphy • 1 Sep 2022
0:50
Challenges for HCPs in Ireland treating multiple myeloma
Philip Murphy • 1 Sep 2022
2:39
Treating patients with multiple myeloma in Ireland
Philip Murphy • 1 Sep 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals